An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.